Table 2.
Patient and disease characteristics: included subjects and remaining members
| Study population (N = 169) | Remaining members (N = 313) | |
|---|---|---|
| Median age (range) at imatinib start in years | 54 (21–86) | 53 (8–85) |
| Males | 92 (54%) | 163 (52%) |
| Continent | ||
| The Americasa | 145 (86%) | 256 (82%) |
| US | 133 (79%) | 240 (77%) |
| Europe | 16 (9%) | 29 (9%) |
| Asia | 4 (2%) | 9 (3%) |
| Africa | 1 (0.6%) | 1 (0.3%) |
| Oceania | 1 (0.6%) | 4 (1%) |
| Unknown | 2 (1%) | 14 (4%) |
| Primary tumor siteb | ||
| Upper-/mid-GI | 86 (51%) | 157 (50%) |
| Bowel | 64 (38%) | 111 (35%) |
| Other | 10 (6%) | 18 (6%) |
| Unknown | 9 (5%) | 27 (9%) |
| Clinical trial participants | 47 (28%) | 21 (7%) |
| Starting dose (mg/d) | ||
| Median (range) | 400 (0–800) | 400 (100–800) |
| Mean (SD) | 527.8 (177.9) | 424.8 (205.7) |
aMembers located in the Americas were almost exclusively in N. America. There was a single member in Costa Rica that was not included in the study and a single study subject in Mexico; no members were in S. America
bPrimary tumor sites were grouped post hoc as: upper-/mid-GI (esophagus, stomach, abdomen, omentum), bowel (small intestine, colon, rectum), other (liver, bladder, pancreas), and unknown